Three Way Takeover Battle: Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced on Friday that it has completed the purchase of a 4.61% stake in Mylan, which gives it legal standing in the Netherlands where Mylan is based.

Teva says the it will enable Teva to commence proceedings before the Dutch Enterprise Chamber, should it become necessary.
Teva added that it “has advised Stichting Preferred Shares Mylan that if the Mylan Extraordinary General Meeting (“EGM”) on the Perrigo transaction is held no later than August 31, 2015, Teva will limit its aggregate shareholding in Mylan prior to the EGM to less than 5 percent of the outstanding shares of Mylan”.

Teva bid over $40 billion to acquire Mylan. Mylen is not interested to be acquired by Teva. On the other hand, Mylan has bid $34 billion to acquire Perrigo Company (NYSE:PRGO; TASE:PRGO). Perrigo says it is only question of price.

Barclays and Greenhill & Co. are serving as financial advisors to Teva. Sullivan & Cromwell LLP is serving as legal counsel to Teva, with De Brauw Blackstone Westbroek N.V. acting as legal advisor in the Netherlands.

READ MORE:

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

By Shiri Habib-Valdhorn On Thursday, June 18th, 2015

Three Way Takeover Battle: Teva’s Mylan Stake Up to 4.3%

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) continues to accumulate shares in takeover target Mylan (MYL), even as Mylan’s largest shareholder, Abbott Labs (NYSE: ABT), announced its More…

(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo

By Shiri Habib-Valdhorn On Thursday, June 18th, 2015

Three Way Takeover Battle: Mylan to List on TASE if Perrigo Bid Succeeds

One of the main worries of Tel Aviv Stock Exchange (TASE) leaders recently has been the expected delisting of Perrigo Company (NYSE:PRGO; TASE:PRGO), if and when the company’s acquisition by Mylan More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

By Jewish Business News Correspondent On Wednesday, June 17th, 2015

Three Way Takeover Battle: Abbott Labs to Back Mylan’s Acquisition of Perrigo

Abbott Laboratories (NYSE: ABT), said it would back the generic pharmaceutical company Mylan’s (MYL) $34 billion bid acquisition of Perrigo Co Plc (PRGO.N). Abbott Lab potentially helping Mylan forfend $40 More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

By Shiri Habib-Valdhorn On Monday, June 15th, 2015

Three Way Takeover Battle: Statistics Weigh Against Teva’s Mylan Bid Succeeding

Will drug company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) succeed in its attempted hostile takeover of rival Mylan (MYL), or will it be Mylan that succeeds in its own hostile takeover More…

L-R Robert-J-Coury-1-Mylan- Teva Erez Vinograd and Yitzhak Peterburg

By Clive Minchom On Monday, June 8th, 2015

Teva Issues New Letter to Mylan NV Confirming Seriousness of Offer to Acquire Mylan

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) issued a new open letter on Monday, signed by both the Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, addressed to Robert More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

By Ilan Shavit On Tuesday, June 2nd, 2015

Mylan to Teva: Stop Playing Games With Our Company

Mylan reports that Teva Pharmaceutical Industries, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake, but did not clarify which anti-trust rule it violated. Five More…

Read more about: , , , , , , , , , , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems